



AKELOS INC. RECEIVES NOTICE OF ALLOWANCE FROM U.S. PATENT AND TRADEMARK OFFICE FOR AKELES AND AKELESS TRADEMARKS

TRADEMARK APPROVALS STRENGTHEN BRAND IDENTITY AND ENHANCE LEGAL PROTECTION

NEW YORK CITY, NY, UNITED STATES, January 6, 2026 /EINPresswire.com/ -- Akelos Inc. announced today that it has received Notices of Allowance from the United States Patent and Trademark Office (USPTO) for its trademark applications for AKELES and AKELESS.

The next step in the trademark registration process will be for Akelos to file Statements of Use for each mark.

These approvals build on the USPTO's renewal of the AKELOS trademark registration for an additional 10-year term, which was approved in January 2025. Together, these actions further solidify the organization's brand identity, will enhance legal protection, and support continued growth and expansion.

Founded in 2018, Akelos Inc. is a biotechnology company developing and commercializing a novel, non-opioid anti-hyperalgesic drug for the treatment of chronic and neuropathic pain. The name "Akelos" is derived from the ancient Greek words ἀκή (aké), meaning "cure" or "remedy," and ἄχος (áchos), meaning "pain" or "grief."

"We're absolutely delighted to reach this important company milestone," said Dr. Steven Fox, Chairman of Akelos Inc.

"We believe our company name is something that physicians, patients, payors, and investors can connect with as we pursue our mission to support the growing number of patients suffering from neuropathic pain—a debilitating condition with limited treatment options."

This trademark progress represents an important step forward for Akelos Inc., strengthening the company's foundation as it advances the development of innovative treatments for neuropathic pain. Akelos remains committed to addressing the significant unmet needs of patients living with chronic pain conditions.

About Akelos

Akelos Inc. has licensed foundational intellectual property from Weill Cornell Medicine to develop

a unique receptor-targeting platform technology. The platform's lead asset is a first-in-class, non-opioid drug with a novel mechanism of action designed for the non-addictive treatment of neuropathic pain.

For more information, visit www.akelosinc.com or connect with Akelos on LinkedIn.

Akelos Forward-Looking Statement

This press release contains forward-looking statements. These forward-looking statements are based on management's expectations and are subject to certain factors, risks, and uncertainties that may cause actual results, outcomes of events, timing, and performance to differ materially from those expressed or implied by such statements. The information contained in this press release is believed to be current as of the date of issuance. Akelos Inc. expressly disclaims any obligation or undertaking to release publicly any updates or revisions to forward-looking statements contained herein to reflect changes in our expectations or changes in events, conditions, or circumstances on which such statements are based.

These statements include, among others, those related to the results of research and development activities; uncertainties relating to preclinical and clinical testing; the cost, timing, and outcome of the regulatory development and approval process; budgets, expenditures, and financing plans; the need for substantial additional funds; patent and intellectual property matters; reliance on third parties, including contract research and contract clinical trial organizations; and market opportunity and competition.

Investor Contact:

Office of Dr. Steven Fox

Phone: +1 212-953-1544

Email: drstevefox@akelosinc.com.

dr steven fox

akelosinc

2129531544

drstevefox@akelosinc.com

Visit us on social media:

Facebook

LinkedIn

Dr. Steven Fox

Akelos Inc

+1 212-953-1544

[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/880922899>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors

try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2026 Newsmatics Inc. All Right Reserved.